• EU approves Daiichi Sankyo and AstraZeneca's Enhertu as adjuvant treatment for HER2-positive early breast cancer with residual disease following neoadjuvant therapy.
• Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 in the phase 3 DESTINY-Breast05 trial.
• The approval triggers a $75 million milestone payment from AstraZeneca to its partner.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610270330BIZWIRE_USPR_____20261026_BW434444) on October 27, 2026, and is solely responsible for the information contained therein.